4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 7.87 USD -2.48% Market Closed
Market Cap: 409m USD
Have any thoughts about
4D Molecular Therapeutics Inc?
Write Note

Wall Street
Price Targets

FDMT Price Targets Summary
4D Molecular Therapeutics Inc

Wall Street analysts forecast FDMT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FDMT is 51 USD with a low forecast of 36.36 USD and a high forecast of 86.1 USD.

Lowest
Price Target
36.36 USD
362% Upside
Average
Price Target
51 USD
548% Upside
Highest
Price Target
86.1 USD
994% Upside

FDMT Last Price Targets
4D Molecular Therapeutics Inc

The latest public price target was made on Sep 19, 2024 by Geulah Livshits from Loop Capital Markets , who expects FDMT stock to rise by 396% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Geulah Livshits
Loop Capital Markets
39 USD
Upside 396%
1 month ago
Sep 19, 2024
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
StreetInsider
Kostas Biliouris
BMO Capital
40 USD
Upside 408%
1 month ago
Sep 19, 2024
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
StreetInsider
Matthew Caufield
H.C. Wainwright
36 USD
Upside 357%
1 month ago
Sep 19, 2024
H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
StreetInsider
Gena Wang
Barclays
45 USD
Upside 472%
6 months ago
Apr 15, 2024
Barclays Starts 4D Molecular Therapeutics (FDMT) at Overweight
StreetInsider
Lisa Walter
RBC Capital
40 USD
Upside 408%
6 months ago
Apr 15, 2024
4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital
StreetInsider
Nalin Tejavibulya
Jefferies
58 USD
Upside 637%
7 months ago
Apr 1, 2024
4D Molecular Therapeutics (FDMT) PT Raised to $58 at Jefferies on multiple catalysts in 2024
StreetInsider
Kostas Biliouris
BMO Capital
63 USD
Upside 701%
7 months ago
Mar 28, 2024
4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
StreetInsider
Kostas Biliouris
BMO Capital
70 USD
Upside 789%
9 months ago
Feb 6, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
Benzinga
Geulah Livshits
Chardan Capital
30 USD
Upside 281%
1 year ago
Jul 5, 2023
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
Benzinga
Show More Price Targets
Show Less Price Targets
Geulah Livshits
Loop Capital Markets
Price Target 39 USD
Upside/Downside 396%
View Source
Kostas Biliouris
BMO Capital
Price Target 40 USD
Upside/Downside 408%
View Source
Matthew Caufield
H.C. Wainwright
Price Target 36 USD
Upside/Downside 357%
View Source
Gena Wang
Barclays
Price Target 45 USD
Upside/Downside 472%
View Source
Lisa Walter
RBC Capital
Price Target 40 USD
Upside/Downside 408%
View Source
Nalin Tejavibulya
Jefferies
Price Target 58 USD
Upside/Downside 637%
View Source
Kostas Biliouris
BMO Capital
Price Target 63 USD
Upside/Downside 701%
View Source
Kostas Biliouris
BMO Capital
Price Target 70 USD
Upside/Downside 789%
View Source
Geulah Livshits
Chardan Capital
Price Target 30 USD
Upside/Downside 281%
View Source
Show More Price Targets
Show Less Price Targets
4D Molecular Therapeutics Inc Competitors:
Price Targets
MGNX
MacroGenics Inc
80% Upside
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
24% Upside
ZNTL
Zentalis Pharmaceuticals Inc
172% Upside
TNG
Transgene SA
244% Upside
6160
Beigene Ltd
16% Upside
REGN
Regeneron Pharmaceuticals Inc
45% Upside
206650
EuBiologics Co Ltd
9% Downside
NVAX
Novavax Inc
136% Upside

Revenue
Forecast

Revenue Estimate
4D Molecular Therapeutics Inc

For the last 5 years the compound annual growth rate for 4D Molecular Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is -31%.

8%
Past Growth
-31%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
4D Molecular Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
4D Molecular Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FDMT's stock price target?
Price Target
51 USD

According to Wall Street analysts, the average 1-year price target for FDMT is 51 USD with a low forecast of 36.36 USD and a high forecast of 86.1 USD.

What is 4D Molecular Therapeutics Inc's Revenue forecast?
Projected CAGR
-31%

For the last 5 years the compound annual growth rate for 4D Molecular Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is -31%.

Back to Top